- <\/ul>\n
- Failed Conservative Management<\/li>\n\n\n\n
- Significant (beyond introitus) and \/ or Symptomatic Prolapse<\/li>\n\n\n\n
- Previous Incontinence \/ Prolapse Surgery<\/li>\n\n\n\n
- Previous Pelvic Irradiation<\/li>\n\n\n\n
- Complicated symptoms (consider referral to urology):\n
- \n
- Haematuria<\/li>\n\n\n\n
- Bladder pain<\/li>\n\n\n\n
- Recurrent UTIs<\/li>\n\n\n\n
- Difficulty with bladder emptying \/ Urinary Retention<\/li>\n\n\n\n
- Suspected fistula<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n
Women with a suspected pelvic mass should be first referred for an Ultrasound Scan to establish a diagnosis and then referred according to the findings.<\/strong><\/p>\n\n\n\n
If symptoms are of sudden onset or atypical, especially in the elderly, bladder malignancy should be considered with early referral urology.<\/p>\n\n\n\n
Who not to refer:<\/h4>\n\n\n\n
- \n
- Women with uncomplicated symptoms who have not<\/strong> undergone initial primary care management<\/li>\n\n\n\n
- Women with urinary symptoms due to a pelvic mass \u2013 this needs urgent investigation first (Ultrasound Scan)<\/li>\n\n\n\n
- Women requiring input from physiotherapy \u2013 please refer directly to generic physiotherapy via SCI Gateway: this is the first line management for all those with any element of stress incontinence (SCI Gateway -AHP-Physiotherapy)<\/a><\/li>\n<\/ul>\n\n\n\n
How to refer:<\/h4>\n\n\n\n
<\/strong>Via SCI Gateway: Specialty Gynaecology \u2013 Urogynaecology<\/p>\n\n\n\n
Referrals Pathway to Women’s Health Physiotherapists in the Community across Edinburgh &Lothians (West\/Mid\/East)via SCI Gateway \u2013 Options:<\/p>\n\n\n\n
AHP \u2013 Physiotherapy. Edinburgh \u2013 Community MSK HUB (Slateford)<\/strong>
AHP \u2013 Physiotherapy. East Lothian \u2013 East Lothian Community Hospital<\/strong> <\/a>Please note – patients can self refer using form <\/a>
AHP \u2013 Physiotherapy. Midlothian – Bonnyrigg Health Centre Please note – patients can self refer using form <\/a><\/strong>
AHP \u2013 Physiotherapy. West Lothian -St Johns Hospital<\/strong><\/p>\n\n\n\n- \n
- Referrals will be directed to one of the Community Physiotherapy Services MSK Outpatient Clinics.<\/li>\n\n\n\n
- Referrals will be triaged appropriately to a Women’s Health Physiotherapist.<\/li>\n<\/ul>\n<\/div><\/div>\n\n\n\nPrimary Care Management<\/span><\/a><\/span><\/div>\n
PRESCRIBING FOR THE TREATMENT OF OVERACTIVE BLADDER IN LOTHIAN
Symptoms of overactive bladder include:
Urinary frequency \/ urgency \/ nocturia with or without urge incontinence
PRIOR TO PRESCRIBING MEDICATION:
1. Exclusion of the following:<\/p>\n\n\n\n- \n
- Haematuria<\/li>\n\n\n\n
- Recurrent urinary tract infection<\/li>\n\n\n\n
- Difficulty with bladder emptying<\/li>\n<\/ul>\n\n\n\n
Any of the above and previous surgery for incontinence warrant early referral
2. Conservative management:<\/p>\n\n\n\n- \n
- Advice regarding fluid intake<\/li>\n\n\n\n
- Bladder retraining<\/li>\n<\/ul>\n\n\n\n
MEDICATION FOR THE OVERACTIVE BLADDER:<\/p>\n\n\n\n
- \n
- Medication should be commenced at the lowest dose and titrated up as required and tolerated. <\/li>\n\n\n\n
- If medication is not effective or not tolerated, the formulation should be changed. <\/li>\n\n\n\n
- The use of medication for overactive bladder may be limited by side effects. These may be reduced by adjusting the dose or changing the formulation \/ application.<\/li>\n<\/ul>\n\n\n\n
Generic antimuscarinic formulations:<\/h4>\n\n\n\n
Tolterodine tartrate <\/strong>(Tablets 1mg, 2mg)<\/p>\n\n\n\n
Dose: 2mg twice daily. Reduced if not tolerated to 1mg twice dailyModified release tablets 4mg once daily<\/p>\n\n\n\n
- \n
- Oxybutynin hydrochloride is no longer on the Lothian Formulary but is the only formulation available for transdermal application if oral application is not tolerated; it should not be used in patients aged over 65 due to increased risk of cognitive impairment<\/li>\n<\/ul>\n\n\n\n
M3 selective antimuscarinic formulations:<\/h4>\n\n\n\n
Solifenacin<\/strong> (Tablets 5mg, 10mg)
Dose: 5mg once daily. Increase to 10mg daily if required<\/p>\n\n\n\nFesoterodine<\/strong> (Tablets 4mg, 8mg) <\/p>\n\n\n\n
Dose: 4mg once daily. Increase to 8mg daily if required<\/p>\n\n\n\n
b3 Receptor agonist:<\/h4>\n\n\n\n
Mirabegron <\/strong>(Tablets 50mg)
Dose: 50mg once daily<\/p>\n\n\n\n- \n
- If antimuscarinic formulations are contra-indicated, not effective in controlling symptoms or not tolerated, the b3-receptor agonist is an alternative option.<\/li>\n\n\n\n
- In patients who are already on medication with a high anticholinergic load, the b3-receptor agonist may be considered as a first line option.<\/li>\n\n\n\n
- The lower dose of Mirabegron 25mg is available for patients with renal or hepatic impairment.<\/li>\n<\/ul>\n\n\n\n
![\"Urogynae](\"\/files\/sites\/2\/Urogynae-Treatrment-of-Overactive-Bladder.png\")
<\/figure>\n<\/div><\/div>\n\n\n\nResources and Links<\/span><\/a><\/span><\/div>\n\u200bPelvic health, Continence and Prolapse education video: https:\/\/vimeo.com\/428502146<\/a><\/p>\n\n\n\n
POGP-PelvicFloor Exercises for women<\/a><\/p>\n\n\n\n
UK Pessary Guideline final April21<\/a><\/p>\n\n\n\n
Management of Female Urinary Symptoms Printable Jan2020<\/a><\/p>\n\n\n\n
Guidance on use of BASICS community <\/a>assessment of bladder function<\/p>\n\n\n\n
Physiotherapy Pelvic Floor Urinary incontinence Prolapse<\/a><\/p>\n\n\n\n
Keeping your bladder healthy leaflet Sept 18<\/a><\/p>\n\n\n\n
Prescribing for the Treatment of Overactive Bladder<\/a><\/p>\n\n\n\n
<\/p>\n<\/div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
Services The Urogynaecology Department offers complete clinical and urodynamic assessment of female patients with pelvic floor dysfunction including lower urinary tract symptoms (LUTS) and incontinence, access to the nurse urogynaecology unit as well as surgical intervention for urinary incontinence and prolapse. 06-07-21<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":3976,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_searchwp_excluded":"","footnotes":""},"categories":[238],"class_list":["post-4499","page","type-page","status-publish","hentry","category-urogynaecology"],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"NHS Lothian","author_link":"https:\/\/apps.nhslothian.scot\/refhelp\/author\/nhs-lothian\/"},"rttpg_comment":0,"rttpg_category":" Urogynaecology<\/a>","rttpg_excerpt":"Services The Urogynaecology Department offers complete clinical and urodynamic assessment of female patients with pelvic floor dysfunction including lower urinary tract symptoms (LUTS) and incontinence, access to the nurse urogynaecology unit as well as surgical intervention for urinary incontinence and prolapse. 06-07-21","_links":{"self":[{"href":"https:\/\/apps.nhslothian.scot\/refhelp\/wp-json\/wp\/v2\/pages\/4499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/apps.nhslothian.scot\/refhelp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/apps.nhslothian.scot\/refhelp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/apps.nhslothian.scot\/refhelp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/apps.nhslothian.scot\/refhelp\/wp-json\/wp\/v2\/comments?post=4499"}],"version-history":[{"count":9,"href":"https:\/\/apps.nhslothian.scot\/refhelp\/wp-json\/wp\/v2\/pages\/4499\/revisions"}],"predecessor-version":[{"id":23843,"href":"https:\/\/apps.nhslothian.scot\/refhelp\/wp-json\/wp\/v2\/pages\/4499\/revisions\/23843"}],"up":[{"embeddable":true,"href":"https:\/\/apps.nhslothian.scot\/refhelp\/wp-json\/wp\/v2\/pages\/3976"}],"wp:attachment":[{"href":"https:\/\/apps.nhslothian.scot\/refhelp\/wp-json\/wp\/v2\/media?parent=4499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/apps.nhslothian.scot\/refhelp\/wp-json\/wp\/v2\/categories?post=4499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
- Oxybutynin hydrochloride is no longer on the Lothian Formulary but is the only formulation available for transdermal application if oral application is not tolerated; it should not be used in patients aged over 65 due to increased risk of cognitive impairment<\/li>\n<\/ul>\n\n\n\n
- Women with uncomplicated symptoms who have not<\/strong> undergone initial primary care management<\/li>\n\n\n\n
Who to refer:<\/h4>\n\n\n\n
Women with symptoms as above and:<\/p>\n\n\n\n
- \n